Puma Biotechnology (PBYI) Revenue (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Revenue came in at $44.8 million in Q1 2026, down 2.59% YoY from $46.0 million in Q1 2025, and down 40.61% on a QoQ basis from $75.5 million in Q4 2025.
Puma Biotechnology (PBYI) Revenue (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Revenue data on file, last reported at $44.8 million in Q1 2026.
- Quarterly Revenue fell 2.59% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.2 million (down 2.38% YoY) and the FY2025 annual result came in at $228.4 million, down 0.91% from the prior year.
- Revenue slipped to $44.8 million in Q1 2026, from $75.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $87.6 million in Q4 2022 to a low of $43.8 million in Q1 2024.
- A 5-year average of $58.2 million and a median of $54.6 million in 2023 frame the typical range for Revenue.
- The widest YoY moves for Revenue: up 58.33% in 2022, down 53.41% in 2022.
- Tracing PBYI's Revenue over 5 years: stood at $87.6 million in 2022, then fell by 17.65% to $72.2 million in 2023, then decreased by 18.15% to $59.1 million in 2024, then increased by 27.72% to $75.5 million in 2025, then plunged by 40.61% to $44.8 million in 2026.
- The last three Revenue figures came in at $44.8 million (Q1 2026), $75.5 million (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 56.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.50 Mn |
| Mar 31, 2026 | 44.81 Mn |
| Dec 31, 2025 | 75.45 Mn |
| Sep 30, 2025 | 54.48 Mn |
| Jun 30, 2025 | 52.44 Mn |
| Mar 31, 2025 | 46.01 Mn |
| Dec 31, 2024 | 59.08 Mn |
| Sep 30, 2024 | 80.54 Mn |
| Jun 30, 2024 | 47.08 Mn |
| Mar 31, 2024 | 43.77 Mn |
| Dec 31, 2023 | 72.18 Mn |
| Sep 30, 2023 | 56.12 Mn |
| Jun 30, 2023 | 54.57 Mn |
| Mar 31, 2023 | 52.78 Mn |
| Dec 31, 2022 | 87.64 Mn |
| Sep 30, 2022 | 57.10 Mn |
| Jun 30, 2022 | 59.52 Mn |
| Mar 31, 2022 | 45.74 Mn |
| Dec 31, 2021 | 55.36 Mn |
| Sep 30, 2021 | 46.25 Mn |